FDA grants Breakthrough Therapy Designation for Xolair (omalizumab) for food allergies
Roche announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Xolair ® (omalizumab) for the prevention of severe allergic reactions following accidental exposure to one or more foods in people with allergies. (Source: Roche Investor Update)
Source: Roche Investor Update - August 13, 2018 Category: Pharmaceuticals Source Type: news

PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington ’s disease
Roche today announced that the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation for the company ’s investigational medicine RG6042 (formerly known as IONIS-HTTRx) for the treatment of people with Huntington’s disease (HD). (Source: Roche Investor Update)
Source: Roche Investor Update - August 3, 2018 Category: Pharmaceuticals Source Type: news

Roche Purchases Shares in Tender Offer for FMI
Roche and Foundation Medicine, Inc. (NASDAQ:FMI) today announced that Roche ’s wholly owned subsidiary 062018 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of Foundation Medicine not already owned by Roche or its affiliates, at a price of $137.0 0 per share in cash. (Source: Roche Investor Update)
Source: Roche Investor Update - July 31, 2018 Category: Pharmaceuticals Source Type: news

Invitation to Roche's Virtual Late Stage Pipeline Event 2018
We are pleased to invite investors and analysts to participate in a live video webcast and conference call on Thursday, 13 September 2018, highlighting development and commercial opportunities within our late stage portfolio. (Source: Roche Investor Update)
Source: Roche Investor Update - July 30, 2018 Category: Pharmaceuticals Source Type: news

Reminder: Invitation to Roche's Virtual Pipeline Event: Phase 2 LADDER results of the Port Delivery System (PDS) with Lucentis to be presented at the 2018 ASRS annual meeting
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Thursday, 2 August 2018, featuring data from the Phase 2 LADDER study of the Port Delivery System (RPDS) with Lucentis to be presented at the American Society of Retina Specialists (ASRS) annual meeting (20-25 July 2018) in Vancouver, Canada. (Source: Roche Investor Update)
Source: Roche Investor Update - July 27, 2018 Category: Pharmaceuticals Source Type: news

Roche presents positive phase II results for the first-ever eye implant demonstrating sustained delivery of a biologic medicine to treat people with neovascular age-related macular degeneration
Roche announced positive, top-line results from the LADDER study, the first successful phase II study of a long-acting delivery device for the treatment of neovascular ( “wet”) age-related macular degeneration (nAMD), a leading cause of blindness globally in people aged 60 and over. (Source: Roche Investor Update)
Source: Roche Investor Update - July 26, 2018 Category: Pharmaceuticals Source Type: news

Roche reports very strong performance in the first half of 2018
In the first half of 2018, Group sales rose 7% to CHF 28.1 billion and core EPS grew 19%. Excluding the effect of the US tax reform, core EPS grew 8%, ahead of sales. Core EPS growth reflects the strong underlying business performance. IFRS net income increased 33%, due to the underlying core results and lower impairment of intangible assets compared to 2017. (Source: Roche Investor Update)
Source: Roche Investor Update - July 26, 2018 Category: Pharmaceuticals Source Type: news

Reminder: Invitation to Roche Analyst Event on Diagnostics Division at AACC 2018
We are pleased to invite you to an analyst event on Tuesday, 31st July 2018 to discuss Roche's Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Exposition in Chicago, Illinois (July 30-August 2, 2018). (Source: Roche Investor Update)
Source: Roche Investor Update - July 24, 2018 Category: Pharmaceuticals Source Type: news

Roche receives CE Mark for its Accu-Chek Solo micropump system
Roche announced today that it has received CE Mark for its Accu Chek ® Solo micropump system. (Source: Roche Investor Update)
Source: Roche Investor Update - July 23, 2018 Category: Pharmaceuticals Source Type: news

Roche to present new data demonstrating the breadth and depth of its Alzheimer ’s programme at the upcoming Alzheimer's Association International Conference
Roche announced today that it will present 16 new data presentations from across its Alzheimer ’s disease (AD) pipeline at this year’s Alzheimer's Association International Conference (AAIC) from 22-26 July in Chicago, Illinois. (Source: Roche Investor Update)
Source: Roche Investor Update - July 20, 2018 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Device Designation for Roche's Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer's disease
Roche announced today, that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Elecsys ® ß-Amyloid (1-42) CSF and Elecsys® Phospho-Tau (181P) CSF. These in vitro diagnostic immunoassays are for the measurement of the ß-Amyloid (1-42) and Phospho-Tau concentrations in cerebrospinal fluid (CSF) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s dis ease (AD) or other causes of dementia. (Source: Roche Investor Update)
Source: Roche Investor Update - July 20, 2018 Category: Pharmaceuticals Source Type: news

Reminder: Invitation to Roche's Half Year Results 2018, Thursday 26th July 2018 - Live video webcast and conference call
Roche will publish its Half Year Results for 2018 prior to the opening of the Swiss Stock Exchange on Thursday, 26th July 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - July 19, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with advanced lung cancer
Roche today announced that the Phase III IMpower132 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of Tecentriq ® (atezolizumab) plus chemotherapy (cisplatin or carboplatin plus pemetrexed) reduced the risk of disease worsening or death (PFS) compared to chemotherapy alone in the initial (first-line) treatment of advanced non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - July 19, 2018 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)
Roche today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as an initial (first-line) treatment for people with advanced or metastatic hepatocellular carcinoma (HCC), the most common form of liver cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - July 18, 2018 Category: Pharmaceuticals Source Type: news

Chugai to In-license ROS1/TRK Inhibitor Entrectinib
(Source: Roche Investor Update)
Source: Roche Investor Update - July 17, 2018 Category: Pharmaceuticals Source Type: news

Reminder: Invitation to Roche Analyst Event on Diagnostics Division at AACC 2018
We are pleased to invite you to an analyst event on Tuesday, 31st July 2018 to discuss Roche's Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Exposition in Chicago, Illinois (July 30-August 2, 2018). (Source: Roche Investor Update)
Source: Roche Investor Update - July 17, 2018 Category: Pharmaceuticals Source Type: news

Phase III CAPSTONE-2 study showed that baloxavir marboxil reduced symptoms in people at high risk of complications from the flu
Roche today announced that the phase III CAPSTONE-2 study assessing the safety and efficacy of baloxavir marboxil in people at high risk of complications from the flu met the study ’s primary objective, and showed superior efficacy in the primary endpoint of time to improvement of influenza symptoms versus placebo The Centers for Disease Control and Prevention (CDC) defines people at high risk for serious flu complications to include adults 65 years of age or older, or thos e who have conditions such as asthma, chronic lung disease, diabetes, or heart disease – for these people, flu can lead to hospitalisation ...
Source: Roche Investor Update - July 17, 2018 Category: Pharmaceuticals Source Type: news

Roche announces submission of supplemental New Drug Application for Venclexta for people with previously untreated acute myeloid leukaemia who are ineligible for intensive chemotherapy
Roche today announced submission of a supplemental New Drug Application (sNDA) to the United States (U.S.) Food and Drug Administration (FDA) for Venclexta  (venetoclax), in combination with a hypomethylating agent or in combination with low dose cytarabine (LDAC), for treatment of people with previously untreated acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. (Source: Roche Investor Update)
Source: Roche Investor Update - July 12, 2018 Category: Pharmaceuticals Source Type: news

Invitation to Roche's Virtual Pipeline Event: Phase 2 LADDER results of the Port Delivery System (PDS) with Lucentis to be presented at the 2018 ASRS annual meeting
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Thursday, 2 August 2018, featuring data from the Phase 2 LADDER study of the Port Delivery System (RPDS) with Lucentis to be presented at the American Society of Retina Specialists (ASRS) annual meeting (20-25 July 2018) in Vancouver, Canada. (Source: Roche Investor Update)
Source: Roche Investor Update - July 11, 2018 Category: Pharmaceuticals Source Type: news

Invitation to Roche Analyst Event on Diagnostics Division at AACC 2018
We are pleased to invite you to an analyst event on Tuesday, 31st July 2018 to discuss Roche's Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Exposition in Chicago, Illinois (July 30-August 2, 2018). (Source: Roche Investor Update)
Source: Roche Investor Update - July 3, 2018 Category: Pharmaceuticals Source Type: news

Roche commences tender offer for all shares of Foundation Medicine, Inc. for US$ 137.00 per share in cash
Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Foundation Medicine, Inc. (NASDAQ: FMI) at a price of US$ 137.00 per share. (Source: Roche Investor Update)
Source: Roche Investor Update - July 2, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpassion130 study showed Roche ’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer
Roche today announced that the Phase III IMpassion130 study met its co-primary endpoint of progression-free survival (PFS). (Source: Roche Investor Update)
Source: Roche Investor Update - July 2, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s RoActemra gains positive CHMP opinion for CAR T-cell-induced cytokine release syndrome
Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of RoActemra ® (tocilizumab) for the treatment of cytokine release syndrome (CRS), in adults and pediatric patients aged two years and older. (Source: Roche Investor Update)
Source: Roche Investor Update - June 29, 2018 Category: Pharmaceuticals Source Type: news

Invitation to Roche's Half Year Results 2018, Thursday 26th July 2018 - Live video webcast and conference call
Roche will publish its Half Year Results for 2018 prior to the opening of the Swiss Stock Exchange on Thursday, 26th July 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - June 28, 2018 Category: Pharmaceuticals Source Type: news

FDA grants Priority Review to Roche ’s baloxavir marboxil for the treatment of influenza
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) and granted Priority Review for baloxavir marboxil as a single-dose, oral treatment for acute, uncomplicated influenza in patients 12 years and older. (Source: Roche Investor Update)
Source: Roche Investor Update - June 26, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s TECENTRIQ in combination with chemotherapy helped people with previously-untreated extensive-stage small cell lung cancer live significantly longer compared to chemotherapy
Roche today announced that the Phase III IMpower133 study met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS) at its first interim analysis. (Source: Roche Investor Update)
Source: Roche Investor Update - June 25, 2018 Category: Pharmaceuticals Source Type: news

Changes to the Roche Enlarged Corporate Executive Committee
Roche today announced that Sophie Kornowski-Bonnet, Head of Roche Partnering and member of the enlarged Corporate Executive Committee since 2012, has accepted a new opportunity and will be leaving the company effective 31 July 2018. (Source: Roche Investor Update)
Source: Roche Investor Update - June 22, 2018 Category: Pharmaceuticals Source Type: news

Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology
Roche and Foundation Medicine, Inc. today announced they have entered into a definitive merger agreement for Roche to acquire the outstanding shares of FMI ’s common stock not already owned by Roche and its affiliates at a price of US$ 137.00 per share in cash. (Source: Roche Investor Update)
Source: Roche Investor Update - June 19, 2018 Category: Pharmaceuticals Source Type: news

New long-term data confirm Roche ’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
Roche today announced data from the final analysis of the CLL11 study evaluating Gazyva ®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm. (Source: Roche Investor Update)
Source: Roche Investor Update - June 15, 2018 Category: Pharmaceuticals Source Type: news

Roche announces new OCREVUS (ocrelizumab) data on long-term disability benefits in primary progressive multiple sclerosis and initiation of two global studies in progressive multiple sclerosis
Roche today announced that new OCREVUS (ocrelizumab) data will be presented at the 4th Congress of the European Academy of Neurology (EAN) from 16 June to 19 June in Lisbon, Portugal. (Source: Roche Investor Update)
Source: Roche Investor Update - June 14, 2018 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery
Roche today announced that the US Food and Drug Administration (FDA) has approved Avastin ® (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin as a single agent, for the treatment of women with advanced (stage III or IV) ovarian cancer following initial surgical resection. (Source: Roche Investor Update)
Source: Roche Investor Update - June 13, 2018 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia
Roche, announced today that the United States Food and Drug Administration (FDA) has approved Venclexta ® (venetoclax) in combination with Rituxan® (rituximab) for the treatment of people with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - June 11, 2018 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s MabThera/Rituxan (rituximab) for pemphigus vulgaris
Roche announced today that the US Food and Drug Administration (FDA) has approved MabThera/Rituxan ® (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare, serious, potentially life-threatening condition characterised by progressive painful blistering of the skin and mucous membranes. (Source: Roche Investor Update)
Source: Roche Investor Update - June 8, 2018 Category: Pharmaceuticals Source Type: news

Save the date: Roche Analyst Event on Diagnostics Division at AACC 2018
We are pleased to invite you to an analyst event on Tuesday, 31st July 2018 to discuss Roche ’s Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Exposition in Chicago, Ilinois (July 30-August 2, 2018). (Source: Roche Investor Update)
Source: Roche Investor Update - June 5, 2018 Category: Pharmaceuticals Source Type: news

FDA grants Priority Review to Roche ’s Hemlibra for people with haemophilia A without factor VIII inhibitors
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Hemlibra® (emicizumab-kxwh) for adults and children with haemophilia A without factor VIII inhibitors. (Source: Roche Investor Update)
Source: Roche Investor Update - June 5, 2018 Category: Pharmaceuticals Source Type: news

Roche presents new data across a range of blood cancers at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Roche presented new data from studies in several blood cancers, including diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML) at the 2018 ASCO Annual Meeting, 1-5 June, in Chicago, IL, United States. (Source: Roche Investor Update)
Source: Roche Investor Update - June 3, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer
Roche today announced that results from the Phase III IMpower131 study showed Tecentriq ® (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) reduced the risk of disease worsening or death (progression-free survival; PFS) by 29 percent compared with chemotherapy (carboplatin and nab-paclitaxel) alone in the initial (first-line) trea tment of people with advanced squamous non-small cell lung cancer (NSCLC) (median PFS=6.3 vs. 5.6 months; hazard ratio [HR]=0.71, 95% CI: 0.60, 0.85, p=0.0001). (Source: Roche Investor Update)
Source: Roche Investor Update - June 2, 2018 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence
Roche today announced that the European Commission (EC) has approved Perjeta ® (pertuzumab) in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence. (Source: Roche Investor Update)
Source: Roche Investor Update - June 1, 2018 Category: Pharmaceuticals Source Type: news

Roche to present data for TECENTRIQ (atezolizumab) from across its genitourinary and gastrointestinal cancer immunotherapy programme at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Roche today announced that data from across its genitourinary (GU) and gastrointestinal (GI) cancer immunotherapy development programme will be presented during the American Society of Clinical Oncology (ASCO) Annual Meeting from 1-5 June in Chicago, IL, United States. (Source: Roche Investor Update)
Source: Roche Investor Update - June 1, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower130 study showed Roche ’s Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) helped people with metastatic non-squamous NSCLC live significantly longer compared to chemotherapy alone
Roche today announced that the Phase III IMpower130 study met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS). (Source: Roche Investor Update)
Source: Roche Investor Update - May 29, 2018 Category: Pharmaceuticals Source Type: news

Reminder: Invitation to Roche Analyst Event at ASCO 2018
We are pleased to invite you to an analyst briefing to discuss data presented on the Roche Group ’s oncology products and pipeline at the American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago (1 – 5 June 2018). (Source: Roche Investor Update)
Source: Roche Investor Update - May 25, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Hemlibra reduced treated bleeds by 96 percent compared to no prophylaxis in phase III HAVEN 3 study in haemophilia A without factor VIII inhibitors
Roche today announced full results from the phase III HAVEN 3 study evaluating Hemlibra ® (emicizumab) prophylaxis administered every week or every two weeks in people with haemophilia A without factor VIII inhibitors and the phase III HAVEN 4 study evaluating Hemlibra prophylaxis administered every four weeks in people with haemophilia A with or without factor VIII inhibitors. (Source: Roche Investor Update)
Source: Roche Investor Update - May 21, 2018 Category: Pharmaceuticals Source Type: news

Reminder: Invitation to Roche ’s Virtual Pipeline Event from WFH 2018 World Congress
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Wednesday, 23 May 2018, from the World Federation of Hemophilia (WFH) 2018 World Congress (20-24 May 2018) in Glasgow, Scotland. (Source: Roche Investor Update)
Source: Roche Investor Update - May 18, 2018 Category: Pharmaceuticals Source Type: news

Follow-up phase III data showed Roche ’s Alecensa helped people with ALK-positive metastatic non-small cell lung cancer live a median of almost three years without their disease worsening or death
Roche today announced follow-up data from the phase III ALEX study, showing that, as an initial treatment, Alecensa ® (alectinib) significantly reduced the risk of disease progression or death (progression-free survival; PFS) by 57% (hazard ratio [HR]= 0.43, 95% CI: 0.32-0.58) compared to crizotinib after two years of follow-up in people with anaplastic lymphoma kinase (ALK)-positive metastatic (advanced) non-sm all cell lung cancer (NSCLC), as assessed by the investigator. (Source: Roche Investor Update)
Source: Roche Investor Update - May 17, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower150 study showed Roche ’s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly longer compared to Avastin plus carboplatin and paclitaxel
Roche today announced positive results from the Phase III IMpower150 study of Tecentriq ® (atezolizumab) and Avastin® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) for the initial (first-line) treatment of chemotherapy-naïve people with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - May 17, 2018 Category: Pharmaceuticals Source Type: news

FDA approves subcutaneous formulation of Actemra for use in active polyarticular juvenile idiopathic arthritis (pJIA), a rare form of juvenile arthritis
Roche announced today that the US Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra ® (tocilizumab) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients two years of age and older. (Source: Roche Investor Update)
Source: Roche Investor Update - May 15, 2018 Category: Pharmaceuticals Source Type: news

Roche to present new phase III data for Hemlibra in people with haemophilia A at the World Federation of Hemophilia 2018 World Congress
Roche today announced that phase III results for Hemlibra ® (emicizumab) will be presented for the first time during the World Federation of Hemophilia (WFH) 2018 World Congress from 20-24 May in Glasgow, Scotland. (Source: Roche Investor Update)
Source: Roche Investor Update - May 14, 2018 Category: Pharmaceuticals Source Type: news

Invitation to Roche ’s Virtual Pipeline Event from WFH 2018 World Congress
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Wednesday, 23 May 2018, from the World Federation of Hemophilia (WFH) 2018 World Congress (20-24 May 2018) in Glasgow, Scotland. (Source: Roche Investor Update)
Source: Roche Investor Update - May 11, 2018 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer
Roche today announced that the Phase III IMblaze370 study evaluating the combination of Tecentriq ® (atezolizumab) and Cotellic® (cobimetinib) did not meet its primary endpoint of overall survival (OS) compared to regorafenib. The study evaluated the combination in people with difficult-to-treat, locally advanced or metastatic colorectal cancer (CRC) whose disease progressed or who were intole rant to at least two systemic chemotherapy regimens. (Source: Roche Investor Update)
Source: Roche Investor Update - May 10, 2018 Category: Pharmaceuticals Source Type: news

Roche to present new data from its industry-leading oncology portfolio at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Roche today announced that new data from its early and late-stage clinical studies, on more than 19 approved and investigational cancer medicines, will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from 1-5 June, in Chicago, IL, United States. More than 180 abstracts have been accepted across 13 cancer types, including two “late breakers” and 15 oral presentations. (Source: Roche Investor Update)
Source: Roche Investor Update - May 8, 2018 Category: Pharmaceuticals Source Type: news